As of May 23, 2025, Paratek Pharmaceuticals Inc (PRTK) reports a EV/EBITDA of -7.74.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Paratek Pharmaceuticals Inc's EV/EBITDA to Peers
To better understand Paratek Pharmaceuticals Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Paratek Pharmaceuticals Inc (PRTK) | -7.74 |
| Xeris Biopharma Holdings Inc (XERS) | 446.47 |
| Fulcrum Therapeutics Inc (FULC) | 201.22 |
| Bristol-Myers Squibb Co (BMY) | 50.47 |
| Catalent Inc (CTLT) | 45.03 |
| Eli Lilly and Co (LLY) | 44.31 |
Compared to its competitors, Paratek Pharmaceuticals Inc's EV/EBITDA is among the lowest compared to peers, which may indicate undervaluation or market concerns about future performance.